Advertisements


Bristol-Myers can be "a sweet pill" for investors, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 12th, 2019

Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors

Wall Street has soured on the deal for Celgene, but Bristol-Myers has one of the lowest valuations in the drug sector and could itself become a takeover target.....»»

Category: topSource: barronsJan 13th, 2019

Barron"s Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More

This weekend's Barron's cover story reveals the results of the Barron's 2019 Investment Roundtable. Other featured articles examine safe dividend growth stocks and the best stock funds for risky markets. read more.....»»

Category: blogSource: benzingaJan 13th, 2019

Should Investors Like Bristol-Myers" Buyout of Celgene?

The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual......»»

Category: topSource: foxnewsJan 7th, 2019

Celgene Investors Should Take the Money and Run

With Celgene stock trading 25% higher after Bristol-Myers Squibb made a $74 billion acquisition offer, Celgene investors probably shouldn’t wait around to see if the deal closes......»»

Category: topSource: barronsJan 4th, 2019

Celgene shareholders should sell now, Leerink says

Bristol-Myers Squibb Co.'s agreement to acquire Celgene Corp. is "an exit opportunity for Celgene shareholders," Leerink analysts wrote in a note to investors Thur.....»»

Category: topSource: marketwatchJan 3rd, 2019

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy......»»

Category: topSource: reutersJul 27th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Bristol-Myers/Celgene: The Spread Is Your Friend

Bristol-Myers/Celgene: The Spread Is Your Friend.....»»

Category: topSource: seekingalpha3 hr. 24 min. ago

Johns Hopkins, Bristol-Myers Face $1 Billion Suit For Infecting Guatemalan Hookers With Syphilis 

A federal judge in Maryland said Johns Hopkins University, pharmaceutical company Bristol-Myers Squibb and the Rockefeller Foundation must face a $1.....»»

Category: blogSource: zerohedgeJan 19th, 2019

The Bristol-Myers Celgene Deal, And Other Ideas

The Bristol-Myers Celgene Deal, And Other Ideas.....»»

Category: topSource: seekingalphaJan 18th, 2019

The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab

Zacks.....»»

Category: topSource: redinewsJan 17th, 2019

Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It

Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It.....»»

Category: topSource: seekingalphaJan 15th, 2019

3 Reasons Bristol-Myers" $90 Billion Mega-Merger Makes It A Must Own Stock

3 Reasons Bristol-Myers" $90 Billion Mega-Merger Makes It A Must Own Stock.....»»

Category: topSource: seekingalphaJan 15th, 2019

Societe General applauds Bristol-Myers" "bold" deal, double upgrades to Buy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 15th, 2019

Bristol-Myers upgraded to Buy from Sell at Societe Generale

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 15th, 2019

Bristol-Myers: EC approves Opdivo plus low dose Yervoy for treatment of RCC

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 14th, 2019

Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene

Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene.....»»

Category: topSource: seekingalphaJan 14th, 2019

Bristol-Myers: Fattening Up The Pipeline With Celgene

Bristol-Myers: Fattening Up The Pipeline With Celgene.....»»

Category: topSource: seekingalphaJan 13th, 2019

One-year ratio spread in Bristol Myers as shares see relative weakness

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 9th, 2019

Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Zacks.....»»

Category: topSource: redinewsJan 9th, 2019